AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02507206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
Study NCT02507206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
Study NCT01414465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
Study NCT01414465 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Orlistat
Description: Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
Study NCT01414465 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Orlistat
Description: Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
Study NCT01088672 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical Thrombectomy
Description: The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
Study NCT01235026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: 5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10\^10 CFU/g), twice a day, for 6 weeks.
Study NCT01235026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6g of maltodextrin, twice a day for 6 weeks.
Study NCT01840150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breath test
Description: Undergo NA-NOSE breath test
Study NCT01840150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01760915 — intervention group
Intervention type: OTHER
Intervention: NC100182 Hyperpolarized 3He
Description: Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
Study NCT04434092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as specified in the respective arms.
Study NCT04434092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crovalimab
Description: Crovalimab will be administered as specified in the respective arms.
Study NCT04434092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Eculizumab will be administered as specified in the respective arm.
Study NCT02841306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Study NCT02498522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: 83 patients will continue metformin until end of 1st trimester
Study NCT02498522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 83 patients will continue metformin until end of 1st trimester
Study NCT01791283 — intervention group
Intervention type: PROCEDURE
Intervention: Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.
Study NCT03463525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.
Study NCT03463525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]osimertinib
Description: Patients will receive 3 single IV microdose administrations of \[11C\]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
Study NCT03758365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study NCT03758365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate 0.05% Lotion
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study NCT03758365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Dipropionate 0.05% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study NCT03758365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 0.1% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study NCT01366703 — intervention group
Intervention type: DEVICE
Intervention: implantable loop recorder Medtronic reveal XT Full view
Description: Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
Study NCT03408509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
Study NCT02033967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vasodilator induced hypovolemia
Study NCT02033967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vasodilator induced hypovolemia
Study NCT00507819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
Study NCT00507819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One placebo capsule will be taken by mouth three times-a-day.
Study NCT02994225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery
Study NCT00970840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-20gM or LNS-P&L
Description: Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P\&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
Study NCT03140410 — intervention group
Intervention type: OTHER
Intervention: Antibiotic resistance
Description: Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated
Study NCT01421225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop Insulin Pump therapy
Description: Subjects insulin doses were adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.
Study NCT01421225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insulin Pump Therapy
Description: Subjects insulin doses followed their usual home routine.
Study NCT03356080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
Study NCT03356080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: cytarabine, iv,15mg/m2 q12h, Day1-Day10
Study NCT03356080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-transretinoic acid
Description: All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
Study NCT03356080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 300ug,sc,Day 0 until CR is achieved
Study NCT00924495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: rTMS therapy daily for two weeks, five times per week each lasting for half an hour
Study NCT01421628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitness exercise program
Description: Exercise program, daily frequency, duration of 6 weeks.
Study NCT03680586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo ultra low-dose radiation
Study NCT00697125 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses
Study NCT00697125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine (208129)
Study NCT00697125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine, experimental formulation
Description: Intramuscular injection, 3 doses
Study NCT05399862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17648 probiotic
Description: Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection
Study NCT05399862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule with no microbial cell preparation
Study NCT02557581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No training
Study NCT02557581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No training
Study NCT02557581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endurance training
Study NCT02557581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Study NCT02557581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Study NCT02557581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Study NCT02557581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Study NCT02557581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Study NCT02557581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02482948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Leptospermum Honey (Medihoney)
Description: STudy agent to be applied to the wound daily.
Study NCT02482948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase
Description: Study agent to be applied daily to the wound.
Study NCT03870308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
Study NCT02981082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl Fumarate (DMF)
Description: Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
Study NCT02981082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
Study NCT02944552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicyclol tablet 25mg
Description: Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
Study NCT04164654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loneliness Intervention
Description: 28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
Study NCT04164654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Loneliness Intervention
Description: 28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
Study NCT00722670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Woman-focused intervention
Description: Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
Study NCT00722670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants in this group only received services that were part of their substance abuse treatment program
Study NCT02944552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicyclol tablet 50mg
Description: Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
Study NCT02944552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyene phosphatidylcholine capsule 456mg
Description: Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
Study NCT03511040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenate Intraluminal Device
Description: Dilation of vasospastic intracranial vessels
Study NCT02476812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Piggy Bank
Description: Already noted.
Study NCT00708214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 at high and medium dosages
Study NCT00708214 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BIBW 2992
Description: BIBW 2992 at high and medium dosages
Study NCT00708214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole at standard dosage
Study NCT00708214 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Letrozole at standard dosage
Study NCT00107289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iobenguane I 131
Description: Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours or for 15 minutes for smaller patients on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year.
Study NCT04042116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
Study NCT04042116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
Study NCT04042116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.
Study NCT04042116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab 480 mg will be administered once every 4 weeks.
Study NCT03402256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
Study NCT01742299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
Study NCT02203552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline hydrochloride
Description: 100 mg bid given by mouth for 9 weeks
Study NCT02203552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo given by mouth for 9 weeks
Study NCT02203552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
Study NCT02203552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
Study NCT02203552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: The CES-D and STAI will be administrated weekly.
Study NCT02203552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire administration
Description: The CES-D and STAI will be administrated weekly.
Study NCT04466150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: open label biomarker study
Study NCT02978625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT02978625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02978625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02978625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02978625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02978625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography
Description: Undergo PET/CT
Study NCT02978625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT
Study NCT00946296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Iodide
Description: 8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
Study NCT03305523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocautery
Description: In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
Study NCT02933801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
Study NCT02933801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given at a dose of 600 mg BID orally on a continuous basis.